glp1versus

Foundayo vs Victoza

orforglipron (GLP-1 receptor agonist (oral small-molecule)) vs liraglutide (GLP-1 receptor agonist) — a complete side-by-side comparison.

Eli Lilly and CompanyNovo Nordisk

Foundayo weight loss

12.4%

Victoza weight loss

3.2%

Foundayo dosing

Once daily

Victoza dosing

Once daily

Reviewed by Dr. Elena Vance, DOLast reviewed 7 sources cited

Quick Summary

Foundayo (orforglipron) and Victoza (liraglutide) are both glp-1 receptor agonist (oral small-molecule)s. In clinical trials, Foundayo showed greater weight loss (12.4% vs 3.2%).

See the comparison table below for detailed side-by-side data.

Foundayo vs Victoza: Full Comparison

FeatureFoundayo(orforglipron)Victoza(liraglutide)
Active Ingredientorforglipronliraglutide
Drug ClassGLP-1 receptor agonist (oral small-molecule)GLP-1 receptor agonist
ManufacturerEli Lilly and CompanyNovo Nordisk
FDA Approved2026-04-012010-01-25
Approved Indications
  • Chronic weight management in adults with obesity (BMI >=30 kg/m^2), or overweight (BMI >=27 kg/m^2) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
  • Type 2 diabetes in patients aged 10+ years
Routeoralsubcutaneous injection
FrequencyOnce dailyOnce daily
Starting Dose3 mg once daily0.6 mg daily
Maintenance Dose12 mg or 36 mg once daily1.2 mg or 1.8 mg daily
Max Dose36 mg once daily1.8 mg daily
Weight Loss (%)12.4%3.2%
A1C ReductionN/A (not indicated for diabetes)1.1%
Key TrialATTAIN-1 (72 weeks)LEADER (188 weeks)
List PricePricing announced at U.S. launch (April 2026); confirm with LillyDirect$950-$1,100/month
With InsuranceFormulary coverage evolving; many commercial plans expected to require prior authorization$25-$150/month (varies by plan)
Savings CardEli Lilly savings program details emerging via LillyDirect$25/month (Novo Nordisk savings card, commercially insured)

Side Effects: Foundayo vs Victoza

Side EffectFoundayoVictoza
Nausea21-27%28%
Diarrhea15-20%17%
Vomiting10-16%11%
Constipation8-14%6%
Indigestion/dyspepsia6-10%Not reported
Abdominal pain5-9%Not reported
Headache5-8%9%
Fatigue4-7%Not reported
Hair loss3-5%Not reported
Pancreatitis (rare)<0.5%<1%
Decreased appetiteNot reported9%
DyspepsiaNot reported7%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Foundayo vs OzempicVictoza vs OzempicFoundayo vs WegovyVictoza vs WegovyFoundayo vs MounjaroVictoza vs MounjaroFoundayo vs ZepboundVictoza vs Zepbound

Frequently Asked Questions

Sources & References

FDA & Regulatory

  1. Foundayo FDA Drugs@FDA approval record — FDA
  2. Victoza FDA Drugs@FDA approval record — FDA

Clinical Trial Records

  1. ATTAIN-1 clinical trial record — ClinicalTrials.gov
  2. LEADER clinical trial record — ClinicalTrials.gov

Peer-Reviewed Literature

  1. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med 2016;375:311-322 — New England Journal of Medicine

Manufacturer Information

  1. Victoza patient and healthcare provider website — Novo Nordisk

Reference Entries

  1. Liraglutide entry on Wikipedia — Wikipedia

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.